CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Nipro Diabetes Systems

Direct Success

Direct Success is a Wall Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agadia

Agadia is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ICORE Healthcare

ICORE Healthcare is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allergy Associates Medical Group

Allergy Associates Medical Group is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.